FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283392305> ?p ?o ?g. }

• W4283392305 endingPage "1038" @default.
• W4283392305 startingPage "1032" @default.
• W4283392305 abstract "Objective Preclinical evidence and early clinical trials have demonstrated the activity of SPL-108, a targeted agent that inhibits CD44 mediated induction of multidrug resistance specifically to paclitaxel and platinum agents. We conducted a phase I, open label, dose escalation study of the safety and tolerability of the combination of SPL-108 with weekly paclitaxel in patients with platinum resistant CD44+ ovarian, primary peritoneal, or fallopian tube cancer. Methods Patients with platinum resistant histologically proven epithelial ovarian, primary peritoneal, or fallopian tube cancers and measurable disease according to RECIST (Response Evaluation Criteria in Solid Tumours) version 1.1 were selected. Tumors were tested for CD44 expression for eligibility, defined as strong (+++) or moderate (++) staining in ≥20% of the tumor tissue or diffuse + staining. Patients were treated with daily and then twice daily SPL-108 subcutaneous injections and weekly intravenous paclitaxel on days 1, 8, and 15 of a 28 day cycle. Endpoints included safety, determination of maximum tolerated dose, and efficacy. Tumors underwent comprehensive genomic profiling, and cell lines and western blotting were used to study markers of response. Results We screened 16 patients, and 14 were enrolled based on CD44+ expression. A total of 86% of patients had high grade serous tumors and all had received multiple prior therapies. There were no grade 4–5 toxicities. One patient had grade 3 peripheral sensory neuropathy attributed to paclitaxel and one patient developed presumed colonic perforation attributed to the study drug. No dose reductions or treatment discontinuations were required. All patients tolerated the maximum planned dose; no maximum tolerated dose was reached. Overall response rate was 36%; 5 (36%) patients had partial response and 5 (36%) patients had stable disease. Conclusions The combination of SPL-108 with weekly paclitaxel was safe and well tolerated. Encouraging antitumor activity was observed, with 72% of patients deriving a clinical benefit. Trial registration NCT03078400 ." @default.
• W4283392305 created "2022-06-25" @default.
• W4283392305 creator A5004910687 @default.
• W4283392305 creator A5007688933 @default.
• W4283392305 creator A5012334511 @default.
• W4283392305 creator A5022661281 @default.
• W4283392305 creator A5026847104 @default.
• W4283392305 creator A5029250695 @default.
• W4283392305 creator A5030729415 @default.
• W4283392305 creator A5030899790 @default.
• W4283392305 creator A5050532635 @default.
• W4283392305 creator A5051087307 @default.
• W4283392305 creator A5055824335 @default.
• W4283392305 creator A5056305566 @default.
• W4283392305 creator A5057491359 @default.
• W4283392305 creator A5057686070 @default.
• W4283392305 creator A5060115232 @default.
• W4283392305 creator A5078968552 @default.
• W4283392305 creator A5081735541 @default.
• W4283392305 creator A5084602925 @default.
• W4283392305 date "2022-06-24" @default.
• W4283392305 modified "2023-10-14" @default.
• W4283392305 title "Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer" @default.
• W4283392305 cites W1545715882 @default.
• W4283392305 cites W1558905924 @default.
• W4283392305 cites W188630526 @default.
• W4283392305 cites W1972230693 @default.
• W4283392305 cites W2004630400 @default.
• W4283392305 cites W2012582486 @default.
• W4283392305 cites W2025192293 @default.
• W4283392305 cites W2030408713 @default.
• W4283392305 cites W2040006430 @default.
• W4283392305 cites W2051960191 @default.
• W4283392305 cites W2073083886 @default.
• W4283392305 cites W2090859762 @default.
• W4283392305 cites W2092482186 @default.
• W4283392305 cites W2109959579 @default.
• W4283392305 cites W2143604295 @default.
• W4283392305 cites W2143904446 @default.
• W4283392305 cites W2154770510 @default.
• W4283392305 cites W2167291962 @default.
• W4283392305 cites W2169455670 @default.
• W4283392305 cites W2170928115 @default.
• W4283392305 cites W2472306545 @default.
• W4283392305 cites W2591862276 @default.
• W4283392305 cites W304933894 @default.
• W4283392305 cites W3081226641 @default.
• W4283392305 cites W3128646645 @default.
• W4283392305 doi "https://doi.org/10.1136/ijgc-2021-003316" @default.
• W4283392305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35750354" @default.
• W4283392305 hasPublicationYear "2022" @default.
• W4283392305 type Work @default.
• W4283392305 citedByCount "2" @default.
• W4283392305 countsByYear W42833923052023 @default.
• W4283392305 crossrefType "journal-article" @default.
• W4283392305 hasAuthorship W4283392305A5004910687 @default.
• W4283392305 hasAuthorship W4283392305A5007688933 @default.
• W4283392305 hasAuthorship W4283392305A5012334511 @default.
• W4283392305 hasAuthorship W4283392305A5022661281 @default.
• W4283392305 hasAuthorship W4283392305A5026847104 @default.
• W4283392305 hasAuthorship W4283392305A5029250695 @default.
• W4283392305 hasAuthorship W4283392305A5030729415 @default.
• W4283392305 hasAuthorship W4283392305A5030899790 @default.
• W4283392305 hasAuthorship W4283392305A5050532635 @default.
• W4283392305 hasAuthorship W4283392305A5051087307 @default.
• W4283392305 hasAuthorship W4283392305A5055824335 @default.
• W4283392305 hasAuthorship W4283392305A5056305566 @default.
• W4283392305 hasAuthorship W4283392305A5057491359 @default.
• W4283392305 hasAuthorship W4283392305A5057686070 @default.
• W4283392305 hasAuthorship W4283392305A5060115232 @default.
• W4283392305 hasAuthorship W4283392305A5078968552 @default.
• W4283392305 hasAuthorship W4283392305A5081735541 @default.
• W4283392305 hasAuthorship W4283392305A5084602925 @default.
• W4283392305 hasBestOaLocation W42833923051 @default.
• W4283392305 hasConcept C121608353 @default.
• W4283392305 hasConcept C126322002 @default.
• W4283392305 hasConcept C126894567 @default.
• W4283392305 hasConcept C141071460 @default.
• W4283392305 hasConcept C143998085 @default.
• W4283392305 hasConcept C1491633281 @default.
• W4283392305 hasConcept C197934379 @default.
• W4283392305 hasConcept C2775883341 @default.
• W4283392305 hasConcept C2776694085 @default.
• W4283392305 hasConcept C2777249960 @default.
• W4283392305 hasConcept C2777292972 @default.
• W4283392305 hasConcept C2778239845 @default.
• W4283392305 hasConcept C2778375690 @default.
• W4283392305 hasConcept C2779984678 @default.
• W4283392305 hasConcept C2780427987 @default.
• W4283392305 hasConcept C2780932548 @default.
• W4283392305 hasConcept C2781451048 @default.
• W4283392305 hasConcept C31760486 @default.
• W4283392305 hasConcept C54355233 @default.
• W4283392305 hasConcept C71924100 @default.
• W4283392305 hasConcept C86803240 @default.
• W4283392305 hasConcept C90924648 @default.
• W4283392305 hasConceptScore W4283392305C121608353 @default.
• W4283392305 hasConceptScore W4283392305C126322002 @default.

• next